21 Participants Needed

SNUG01 for ALS

Recruiting at 3 trial locations
JS
Overseen ByJi Shen
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: SineuGene Therapeutics Co., Ltd.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of SNUG01 in in adult subjects with Amyotrophic Lateral Sclerosis (ALS).

Are You a Good Fit for This Trial?

This trial is for adults with Amyotrophic Lateral Sclerosis (ALS). Specific eligibility criteria are not provided, but typically include factors like disease stage and overall health. People who meet certain conditions that the study outlines may be excluded.

Inclusion Criteria

I have been diagnosed with ALS according to specific medical criteria.
Subjects who are able to provide written informed consent form (ICF)
I am between 18 and 80 years old.
See 4 more

Exclusion Criteria

Serum Anti-AAV9 neutralizing antibody titer ≥ 1:100
Subjects who have implanted or are estimated to require a diaphragmatic pacing system during the study period
I have been treated with gene therapy, stem cell products, or had an organ transplant.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation and Expansion

Participants receive ascending dose levels of SNUG01 via single intrathecal injection

52 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

up to 1 year

What Are the Treatments Tested in This Trial?

Interventions

  • SNUG01
Trial Overview The trial is testing SNUG01's safety, how well patients can tolerate it, and its initial effectiveness in treating ALS. This involves observing any changes in the condition or symptoms of ALS after administering SNUG01.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: 3 Ascending Dose Levels, Single Injection by Intrathecal(IT)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

SineuGene Therapeutics Co., Ltd.

Lead Sponsor

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security